At a glance
- Company
- VERAXA Biotech
- Ticker
- NASDAQ: VRXA
- Announcement
- Financing
Key figures
- Votes cast in favor
- more than 99.94%
- Outstanding share capital represented
- 72.20%
- Capital band end date
- Dec. 31, 2030
- Current maximum board size
- five
- New maximum board size
- seven
Products and programs
VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company’s outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030 and an increase in the maximum size of the board of directors from five to seven members.
The company said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital markets activities and continued development of its BiTAC(R) technology platform and oncology pipeline. Management said the vote reflects strong shareholder support for VERAXA’s strategy of advancing antibody-based cancer therapeutics while pursuing long-term value creation.
To view the full press release, visit https://ibn.fm/qfL87
About VERAXA Biotech AG
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
In brief
VERAXA Biotech says shareholders approved every proposal presented at its Extraordinary General Meeting. The company reported that more than 99.94% of votes cast supported the measures, with 72.20% of outstanding share capital represented. Approved changes include conditional share capital for options and warrants, a capital band that runs through Dec. 31, 2030, and authority to expand the board from five to seven members. VERAXA says the measures are intended to give it greater flexibility for potential acquisitions, collaborations, investment projects and capital-markets activity. It also plans to use the framework to support development of its BiTAC technology platform and oncology pipeline. Management said the shareholder vote reflects support for its approach to advancing antibody-based cancer treatments and pursuing long-term value creation.
Key takeaways
- Shareholders approved all proposals at VERAXA Biotech’s Extraordinary General Meeting.
- More than 99.94% of votes cast favored the measures; 72.20% of share capital was represented.
- Approved measures include conditional share capital and a capital band through Dec. 31, 2030.
- The maximum board size will increase from five to seven members.
SEC filings
Earlier from VERAXA Biotech AG
- VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
- VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany
- VERAXA Biotech (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
- VERAXA Biotech (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development
- VERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership
